KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Recruiting now · Phase 2/Phase 3

Conditions studied: Myasthenia Gravis, Generalized Myasthenia Gravis

In brief

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

Key facts

Study ID
NCT06193889
Run by
Kyverna Therapeutics
People needed
66
Starts
2024-08-28
Expected to finish
2028-09-01
Last updated by the study team
2026-07-29

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.